No Detail Found!

Concomitant Use of Ado-trastuzumab Emtansine and Imatinib in a Patient of CML and Metastatic Breast Cancer

Author(s)
Cengiz Karacin Department of Medical Oncology, HSU Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital,Ankara,Turkey
Irem Bilgetekin Department of Medical Oncology, HSU Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital,Ankara,Turkey
Fatma Bugdayci Basal Department of Medical Oncology, HSU Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital,Ankara,Turkey
Omur Berna Oksuzoglu Department of Medical Oncology, HSU Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital,Ankara,Turkey
Abstract
Imatinib is a CYP3A4 inhibitor, while ado-trastuzumab is a CYP3A4 substrate. Imatinib can interact with ado-trastuzumab emtansine (T-DM1) and can increase T-DM1 concentrations, leading to T-DM1-related toxicity. There is no trial or case report in the literature on the concomitant use of Imatinib and T-DM1. Herein, we report a case in which T-DM1 was used e ectively with imatinib in a patient with chronic myeloid leukaemia (CML) and metastatic Her-2-positive breast cancer. A 37-year female using imatinib for CML was diagnosed with breast cancer and a modi ed radical mastectomy was performed. Skin metastasis occurred within one year after adjuvant therapy was completed. Lung metastasis occurred after Trastuzumab + vinorelbine treatment and T-DM1 and imatinib were given to the patient. No side e ects were observed except for grade 1 fatigue. This case report is the rst to report the concomitant use of T-DM1 and imatinib in a patient of CML and metastatic breast cancer.
Publication Details
Page(s) 1501-1502
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 32, Issue: 11, Year: 2022

Request the full text from PASTIC

Keywords
Breast Cancer, Chronic myeloid leukaemia, Imatinib, Ado-trastuzumab emtansine
0

Citations

0

Downloads

82

Views